IL-13 inhibitor Ebglyss (lebrikizumab) has been recommended (PDF) by cost-effectiveness agency NICE for people aged 12 and over with moderate-to-severe atopic dermatitis that has not responded to ...

The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in Germany next year.

Lilly added that the study also showed Ebglyss was able to achieve meaningful improvements in patients with difficult-to-treat dermatitis on the face and hands. The company said patients in the ...

The company's dermatology business is driven by Ebglyss (lebrikizumab) and Ilumetri (tildrakizumab). The company further reveals that these medications are anticipated to lead to over EUR800m ($ ...

Of the 147 lebrikizumab-treated patients that did not achieve protocol-defined responses by week 16, 36.1% achieved IGA 0 or 1 by week 52. 75.5% and 44.2% also achieved EASI 75 and EASI 90.